Navigation Links
Sanofi Pasteur Announces Results of U.S. Clinical Trials in Adults Following One Dose of Influenza A (H1N1) Vaccine
Date:10/1/2009

identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    Contacts

    Global Media Relations                 US Media Relations
    Pascal Barollier                       Donna Cary
    T. +33-(0)4-37-37-50-38                T. +1-570-957-0717
    pascal.barollier@sanofipasteur.com     donna.cary@sanofipasteur.com
    www.sanofipasteur.com                  www.sanofipasteur.us

SOURCE Sanofi Pasteur


'/>"/>
SOURCE Sanofi Pasteur
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
10. Sanofi-aventis Stands Behind the Safety of Lantus(R)
11. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... 2015  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... announced the appointment of Joann V. Lofgren ... Market Development, effective July 6, 2015. In this role, ... executing on the company,s market and product development strategy ... to welcome Joann to the OncoSec team and have ...
(Date:7/5/2015)... TOKYO , July 6, 2015 ... first international symposium on Medical-Engineering Collaboration "Medicine ... on July 10, 2015 in Tokyo, ... or its medical applied research will present their ... technology and a new industry produced with 8K ...
(Date:7/4/2015)... Adding SIR-Spheres® Y-90 resin ... metastatic colorectal cancer in the liver (mCRC) further ... Patients with unresectable metastatic colorectal cancer (mCRC) that ... greatest improvement in Progression-Free Survival (PFS) in the ... microspheres to a current first-line chemotherapy regimen, according ...
Breaking Medicine Technology:OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 2OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development 3Nihon University to Host International Symposium on Medical-Engineering Collaboration 2Nihon University to Host International Symposium on Medical-Engineering Collaboration 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 2New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 3New SIRFLOX Study Data Presented at World Congress of Gastrointestinal Cancer 4
... MATEO, Calif., Feb. 28, 2011 Nile Therapeutics, Inc. ... the development of novel therapeutics for heart failure patients, ... MDT ) on the clinical development of ... failure and renal disease applications. "We are ...
... 2011 Hotspur Technologies announced today that Dr. ... clinical use of its Keeper™ Embolectomy Catheter.  The ... within arteries, while also incorporating the capability of ... The Keeper Catheter combines a compliant ...
Cached Medicine Technology:Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 2Nile Therapeutics to Collaborate with Medtronic on Clinical Development of Cenderitide for Heart Failure and Renal Disease 3Hotspur's Keeper Embolectomy Catheter Deployed for First Time 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... stages of drug discovery. iPSCs are generated from adult cells, such as blood ... cell type in the human body. , iPSC-derived cardiomyocytes have ...
(Date:7/6/2015)... ... 2015 , ... “ TapGlance ” was featured on NewsWatch as part of ... the market for iOS, Android, and Windows. Joe Toohey, the host of AppWatch and ... app helps users visualize what rooms will look like before they even start renovating.. ...
(Date:7/6/2015)... ... ... report titled “ Female Hair Loss Needs to be Talked About, Shed Stigma, Experts Say,” ... U.S. will suffer from thinning hair or hair loss . For these 30 million women, ... queen, who was interviewed for the report began losing her hair at age 11 due to ...
(Date:7/6/2015)... York, NY (PRWEB) , ... July 06, 2015 ... ... their health care from nurses or midwives, yet there is a large gap ... nursing and midwifery research required to improve health outcomes and reduce unnecessary or ...
(Date:7/6/2015)... ... 2015 , ... Olive Fertility Centre is proud to announce that Olive medical ... behalf of the department of Family Practice. , “This award is a real honour,” ... The technology is changing so rapidly and we are also developing new models of ...
Breaking Medicine News(10 mins):Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2Health News:Olive Fertility Centre Physician Honoured for Teaching 2
... Heart surgeons are getting ready for the first heart valve ... ,The operation is scheduled for Tuesday and will be performed ... is termed as percutaneous aortic valve replacement. This technique called ... , The novelty of this surgery is that it ...
... A new study conducted by New Agricultural Research Service ... varying thickening capacity //and this information is expected to ... ,Peanut flour is obtained after partial extraction of oil ... products, nutrition bars and snacks, marinades, sauces and dressings ...
... Minister Girija Prasad Koirala's sister-in-law and Nepal's most ... problems and other infections in hospital, media reports ... Shahid Gangalal National Heart Centre, the same hospital ... treatment and observation for nearly a week last ...
... a healthcare presentation into Japanese for an American client who ... a task not many can undertake. //And all this from ... Matheson, is proving that it is possible. Specialising in providing ... by delivering on the dot and raking in millions of ...
... hazards and a frenetic job pace increases the likelihood ... new systematic review suggests.// ,Work setting also ... of injury, with food service and construction industry jobs ... group. ,“These studies provide sufficient evidence that ...
... most commonly prescribed antidepressants are similar in effectiveness to ... side effects, according to an analysis// released today by ... ,The findings, based on a review of nearly 300 ... in 10 adult patients get some relief from the ...
Cached Medicine News:Health News:Nepal's Most Influential Woman 'Critically' Ill 2Health News:Cashing in on IT for Healthcare 2Health News:Workplace Pressures, Hazards Raise Risk of Job Injuries in Youths 2Health News:Workplace Pressures, Hazards Raise Risk of Job Injuries in Youths 3Health News:Newer Class of Antidepressants Similar in Effectiveness, Side Effects Differ 2Health News:Newer Class of Antidepressants Similar in Effectiveness, Side Effects Differ 3
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: